Market Cap (In TWD)
3.35 Billion
Revenue (In TWD)
-
Net Income (In TWD)
-170.92 Million
Avg. Volume
78.31 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 43.85-80.9
- PE
- -
- EPS
- -
- Beta Value
- 0.938
- ISIN
- TW0006634009
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Kaimin Chu M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.sinewpharma.com
- Ipo Date
- 2017-06-30
- Details
- Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
More Stocks
-
PANW
-
CDTAFinfinitii ai inc.
CDTAF
-
FEDFINA
-
OVBC
-
6944
-
MNPR
-
CCNEP
-
TMUST-Mobile US, Inc.
TMUS